BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 24052234)

  • 1. Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody.
    Omidfar K; Amjad Zanjani FS; Hagh AG; Azizi MD; Rasouli SJ; Kashanian S
    Mol Biol Rep; 2013 Dec; 40(12):6737-45. PubMed ID: 24052234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.
    Roovers RC; Laeremans T; Huang L; De Taeye S; Verkleij AJ; Revets H; de Haard HJ; van Bergen en Henegouwen PM
    Cancer Immunol Immunother; 2007 Mar; 56(3):303-317. PubMed ID: 16738850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies.
    Tripathy RK; Pande AH
    Life Sci; 2024 May; 345():122593. PubMed ID: 38554946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzymatic ligation of an antibody and arginine 9 peptide for efficient and cell-specific siRNA delivery.
    Ando Y; Nakazawa H; Miura D; Otake M; Umetsu M
    Sci Rep; 2021 Nov; 11(1):21882. PubMed ID: 34750461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the single cell gel electrophoresis (comet assay) for comparing apoptotic effect of conventional antibodies versus nanobodies.
    Shaker GH; Melake NA
    Saudi Pharm J; 2012 Jul; 20(3):221-7. PubMed ID: 23960797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-nanoparticle conjugates to enhance the sensitivity of ELISA-based detection methods.
    Billingsley MM; Riley RS; Day ES
    PLoS One; 2017; 12(5):e0177592. PubMed ID: 28494030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanobody-based immunosensing methods for safeguarding public health.
    Zhang J; Sun H; Pei W; Jiang H; Chen J
    J Biomed Res; 2021 Jul; 35(4):318-326. PubMed ID: 34421007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A robust pipeline for rapid production of versatile nanobody repertoires.
    Fridy PC; Li Y; Keegan S; Thompson MK; Nudelman I; Scheid JF; Oeffinger M; Nussenzweig MC; Fenyƶ D; Chait BT; Rout MP
    Nat Methods; 2014 Dec; 11(12):1253-60. PubMed ID: 25362362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided Surgery.
    Debie P; Devoogdt N; Hernot S
    Antibodies (Basel); 2019 Jan; 8(1):. PubMed ID: 31544818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naturally occurring antibodies devoid of light chains.
    Hamers-Casterman C; Atarhouch T; Muyldermans S; Robinson G; Hamers C; Songa EB; Bendahman N; Hamers R
    Nature; 1993 Jun; 363(6428):446-8. PubMed ID: 8502296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lateral Flow Assay: A Summary of Recent Progress for Improving Assay Performance.
    Omidfar K; Riahi F; Kashanian S
    Biosensors (Basel); 2023 Aug; 13(9):. PubMed ID: 37754072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single Domain Antibody application in bacterial infection diagnosis and neutralization.
    Qin Q; Liu H; He W; Guo Y; Zhang J; She J; Zheng F; Zhang S; Muyldermans S; Wen Y
    Front Immunol; 2022; 13():1014377. PubMed ID: 36248787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of camelid monoclonal nanobody against SLC39A6 zinc transporter protein.
    Ghaderi H; Noormohammadi Z; Habibi-Anbouhi M; Kazemi-Lomedasht F; Behdani M
    Iran J Basic Med Sci; 2021 Dec; 24(12):1726-1733. PubMed ID: 35432806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR-Targeted Photodynamic Therapy.
    Ulfo L; Costantini PE; Di Giosia M; Danielli A; Calvaresi M
    Pharmaceutics; 2022 Jan; 14(2):. PubMed ID: 35213974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotective Effect of the Recombinant Anti-IL-6R Fusion Proteins by Inhibiting JAK2/STAT3 Signaling Pathway in Diabetic Nephropathy.
    Zhang N; Zheng Q; Wang Y; Lin J; Wang H; Liu R; Yan M; Chen X; Yang J; Chen X
    Front Pharmacol; 2021; 12():681424. PubMed ID: 34054555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy.
    Sun S; Ding Z; Yang X; Zhao X; Zhao M; Gao L; Chen Q; Xie S; Liu A; Yin S; Xu Z; Lu X
    Int J Nanomedicine; 2021; 16():2337-2356. PubMed ID: 33790553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanobody: a promising toolkit for molecular imaging and disease therapy.
    Bao G; Tang M; Zhao J; Zhu X
    EJNMMI Res; 2021 Jan; 11(1):6. PubMed ID: 33464410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanobodies in cancer.
    Verhaar ER; Woodham AW; Ploegh HL
    Semin Immunol; 2021 Feb; 52():101425. PubMed ID: 33272897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
    Bannas P; Hambach J; Koch-Nolte F
    Front Immunol; 2017; 8():1603. PubMed ID: 29213270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat Cancer.
    Van Audenhove I; Gettemans J
    EBioMedicine; 2016 Jun; 8():40-48. PubMed ID: 27428417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.